[A20-03] Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73
Last updated 20.03.2020
Project no.:
A20-03
Commission:
Commission awarded on 06.01.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib
Conclusion of dossier assessment A19-73 unchanged: proof of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-73 | Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.